Vai al contenuto principale
Logo Università
Logo di Dipartimento di Scienze Cliniche e Biologiche

Dipartimento di Scienze Cliniche e Biologiche

Dipartimento di Scienze Cliniche e Biologiche

Logo di Dipartimento di Scienze Cliniche e Biologiche

Sarah Allegra

Ricercatore/Ricercatrice a tempo determinato di tipo A

Contatti

Presso

  • Dipartimento di Scienze Cliniche e Biologiche
  • Corso di laurea in Infermieristica - Cuneo

Curriculum vitae

  • Curriculum Vitae (0.3 MB)

    • Prodotti della ricerca selezionati

    1. Allegra, S.; Chiara, F; Di Grazia, D.; Gaspari, M.; De Francia, S. Evaluation of Sex Differences in Preclinical Pharmacology Research: How Far Is Left to Go? Accapted for publication Pharmaceuticals 2023

    2. De Francia, S.; Chiara, F; Allegra, S. COVID-19 Prevention and Treatment. Life 2023, 13(3), 834; https://doi.org/10.3390/life13030834

    3. Allegra, S.; De Francia, S.; Turco, F.; Bertaggia, I.; Chiara, F.; Armando, T.; Storto, S.; Mussa; M.V. Phytotherapy and Drugs: Can Their Interactions Increase Side Effects in Cancer Patients? J. Xenobiot. 2023, 13(1), 75-89; https://doi.org/10.3390/jox13010007

    4. Allegra, S. Cancer Genetics and Clinical Research. Journal of Personalized Medicine, 2022 October 4, 12(10), 1649. 10.3390/jpm12101649

    5. Allegra, S.; Puglisi, S.; Borin, C.; Chiara, F.; Basile, V.; Calabrese, A.; Reimondo, G.; De Francia, S. Sex-Based Evaluation of Lipid Profile in Postoperative Adjuvant Mitotane Treatment for Adrenocortical Carcinoma. Biomedicines 2022, 10, 1873. https://doi.org/10.3390/ biomedicines10081873

    6. Chiara F.*, Allegra S.*, Brescia I., Arrigo E., De Francia S. Influence of seasonal variation and gender on anti-epileptic drugs pharmacokinetics. Ital J Gender-Specific Med 2022;8(3):127-134
    doi 10.1723/3927.39106

    7. Cusato J, Palermiti A, Manca A, Mula J, Antonucci M, De Nicolò A, Allegra S, De Francia S, Chiara F, Di Perri G, Rosa FG, Calcagno A, D'Avolio A. Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants. Pharmaceuticals (Basel). 2022 May 20;15(5):630. doi: 10.3390/ph15050630. PMID: 35631455.

    8. De Francia S, Ferretti A, Chiara F, Allegra S, Mancardi D, Allice TG, Milia MG, Gregori G, Burdino E, Avanzini C, Ghisetti V, Durio A. The Influence of Sex, Gender, and Age on COVID-19 Data in the Piedmont Region (Northwest Italy): The Virus Prefers Men. Life (Basel). 2022 Apr 26;12(5):643. doi:10.3390/life12050643. PMID: 35629311.

    9. Montarolo F, Martire S, Chiara F, Allegra S, De Francia S, Hoxha E, Tempia F, Capobianco MA, Bertolotto A. NURR1-deficient mice have age- and sex-specific behavioral phenotypes. J Neurosci Res. 2022 May 20. doi: 10.1002/jnr.25067. PMID: 35593070.

    10. De Francia S, Berchialla P, Armando T, Storto S, Allegra S, Sciannameo V, Soave G, Sprio AE, Racca S, Caiaffa MR, Ciuffreda L, Mussa MV. “Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?” Eur J Clin Pharmacol. 2022 Feb 22. doi: 10.1007/s00228-022-03298-y.

    11. De Francia S., Mancardi D., Berchialla P., Armando T., Storto S., Allegra S., Soave G., Racca S., Chiara F., Carnovale J., Ciuffreda L., Mussa MV. “Gender-specific side effects of chemotherapy in pancreatic cancer patients” Canadian Journal of Physiology and Pharmacology, 21 October 2021. https://doi.org/10.1139/cjpp-2021-0622.

    12. Piolatto A, Berchialla P, Allegra S, De Francia S, Battista Ferrero G, Piga A, Longo F. “Pharmacological and clinical evaluation of deferasirox formulations for treatment tailoring” Scientific Reports. 2021, 11(1), 12581.

    13. Allegra S, Puglisi S, Brescia I, Chiara F, Basile V, Calabrese A, Reimondo G, De Francia S. Sex Differences on Mitotane Concentration and Treatment Outcome in Patients with Adrenocortical Carcinoma. Life (Basel). 2021 Mar 23;11(3):266. doi: 10.3390/life11030266. PMID: 33807024; PMCID: PMC8004922.

    14. Allegra S, De Francia S, De Nicolò A, Cusato J, Avataneo V, Manca A, Antonucci M, D'Avolio A. Effect of age and gender on voriconazole trough concentrations in adult patients. Eur J Drug Metab Pharmacokinet. 2020 Jun;45(3):405-412. doi: 10.1007/s13318-019-00603-6. PMID: 319655530

    15. Montarolo F, Martire S, Perga S, Spadaro M, Brescia I, Allegra S, De Francia S, Bertolotto A. NURR1 deficiency is associated to ADHD-like phenotypes in mice. Transl Psychiatry. 2019 Aug 27;9(1):207. doi: 10.1038/s41398-019-0544-0. PMID: 31455763.

    16. Renne SL*, Woo HY*, Allegra S*, Rudini N, Yano H, Donadon M, Viganò L, Akiba J, Lee HS, Rhee H, Park YN, Roncalli M, Di Tommaso L. Vessels Encapsulating Tumor Clusters (VETC) Is a Powerful Predictor of Aggressive Hepatocellular Carcinoma. Hepatology. 2019 Jun 17. doi: 10.1002/hep.30814. PMID: 31206715.

    17. Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A. Different Underlying Mechanism Might Explain the Absence of a Significant Difference in Area Under the Concentration-Time Curve of Linezolid for Different ABCB1 Genotypes. Ther Drug Monit. 2019 Apr;41(2):254-255. doi: 10.1097/FTD.0000000000000596. PMID: 30883522.

    18. Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Avataneo V, De Nicolò A, Piga A, D'Avolio A. The effect of vitamin D pathway genes and deferasirox pharmacogenetics on liver iron in thalassaemia major patients. Pharmacogenomics J. 2019 Jan 17. doi: 10.1038/s41397-019-0071-7. PMID: 30651574.

    19. Allegra S, Cardellino CS, Fatiguso G, Cusato J, De Nicolò A, Avataneo V, Bonora S, D'Avolio A, Di Perri G, Calcagno A. Effect of ABCC2 and ABCG2 Gene Polymorphisms and CSF-to-Serum Albumin Ratio on Ceftriaxone Plasma and Cerebrospinal Fluid Concentrations. J Clin Pharmacol. 2018 Dec;58(12):1550-1556. doi: 10.1002/jcph.1266. PMID: 29873816.

    20. Allegra S, Di Paolo A, Cusato J, Fatiguso G, Arrigoni E, Danesi R, Corcione S, DʼAvolio A. A Common mdr1 Gene Polymorphism is Associated With Changes in Linezolid Clearance. Ther Drug Monit. 2018 Oct;40(5):602-609. doi: 10.1097/FTD.0000000000000536. PMID: 29979333.

    21. Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Avataneo V, De Nicolò A, Piga A, D'Avolio A. Role of CYP1A1, ABCG2, CYP24A1 and VDR gene polymorphisms on the evaluation of cardiac iron overload in thalassaemia patients. Pharmacogenet Genomics. 2018 Sep;28(9):199-206. doi: 10.1097/FPC.0000000000000348. PMID: 30179981.

    22. Allegra S, Fatiguso G, Francia S, Pirro E, Carcieri C, Cusato J, Nicolò A, Avataneo V, Perri GD, D'Avolio A. Pharmacogenetic of voriconazole antifungal agent in pediatric patients. Pharmacogenomics. 2018 Jul 1;19(11):913-925. doi: 10.2217/pgs-2017-0173. PMID: 29914286.

    23. Allegra S, Cusato J, De Francia S, Arduino A, Longo F, Pirro E, Massano D, De Nicolò A, Piga A, D'Avolio A. Role of CYP24A1, VDR and GC gene polymorphisms on deferasirox pharmacokinetics and clinical outcomes. Pharmacogenomics J. 2018 May 22;18(3):506-515. doi: 10.1038/tpj.2017.43.
    PMID: 29160302.

    24. Allegra S, Massano D, De Francia S, Longo F, Piccione F, Pirro E, Cusato J, D'Avolio A, Piga A. Clinical relevance of deferasirox trough levels in β-thalassemia patients. Clin Exp Pharmacol Physiol. 2018 Feb;45(2):213-216. doi: 10.1111/1440-1681.12879. PMID: 29205450.

    25. De Nicolò A, Boglione L, Cusato J, Fatiguso G, Favata F, Allegra S, Cariti G, Di Perri G, D'Avolio A. Correlation between entecavir penetration in peripheral blood mononuclear cells and HBV DNA decay during treatment of HBeAg-negative chronic hepatitis B. Antivir Ther. 2018;23(4):373-377. doi: 10.3851/IMP3207. PMID: 29168696.

    26. Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicolò A, Cusato J, Di Perri G, D'Avolio A. Therapeutic drug monitoring of voriconazole for treatment and prophylaxis of invasive fungal infection in children. Br J Clin Pharmacol. 2018 Jan;84(1):197-203. doi: 10.1111/bcp.13401. PMID: 28805964

    27. Avataneo V, De Nicolò A, Rabbia F, Sciandra M, Tosello F, Cusato J, Perlo E, Fatiguso G, Allegra S, Favata F, Mulatero P, Veglio F, Di Perri G, D'Avolio A. A simple UHPLC-PDA method with a fast dilute-and-shot sample preparation for the quantification of canrenone and its prodrug spironolactone in human urine samples. J Pharmacol Toxicol Methods. 2018 Nov - Dec;94(Pt 2):29-35. doi: 10.1016/j.vascn.2018.08.003. PMID: 30165207.

    28. Allegra S, Cusato J, De Francia S, Longo F, Pirro E, Massano D, Piga A, D'Avolio A. Effect of pharmacogenetic markers of vitamin D pathway on deferasirox pharmacokinetics in children. Pharmacogenet Genomics. 2018 Jan;28(1):17-22. doi:10.1097/FPC.0000000000000315. PMID: 29099735.

    29. Cusato J*, Allegra S*, Nicolò A, Calcagno A, D'Avolio A. Precision medicine for HIV: where are we? Pharmacogenomics. 2018 Jan;19(2):145-165. doi: 10.2217/pgs-2017-0123. Review. PMID: 29202676.

    30. Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicolò A, Cusato J, Di Perri G, D'Avolio A. Evaluation of Posaconazole Pharmacokinetics in Adult Patients with Invasive Fungal Infection. Biomedicines. 2017 Nov 20;5(4). pii: E66. doi: 10.3390/biomedicines5040066. PMID: 29156624

    31. Allegra S, Fatiguso G, De Francia S, Favata F, Pirro E, Carcieri C, De Nicolò A, Cusato J, Di Perri G, D'Avolio A. Pharmacokinetic evaluation of oral itraconazole for antifungal prophylaxis in children. Clin Exp Pharmacol Physiol. 2017 Nov;44(11):1083-1088. doi: 10.1111/1440-1681.12822. PMID: 28744925.

    32. Cusato J, De Francia S, Allegra S, Carrella S, Pirro E, Piccione FM, De Martino F, Ferrero A, Daffara FC, Terzolo M, Berruti A, Di Carlo F, Tampellini M, D'Avolio A. Circannual variation of mitotane and its metabolites plasma levels in patients with adrenocortical carcinoma. J Pharm Pharmacol. 2017 Nov;69(11):1524-1530. doi: 10.1111/jphp.12798. PMID: 28809444.

    33. Corcione S, D'Avolio A, Allegra S, Fanelli V, Urbino R, Ranieri MV, Di Perri G, De Rosa FG. Pharmacokinetics of linezolid in critically ill patients: impact of continuous venovenous haemofiltration. Int J Antimicrob Agents. 2017 Jun;49(6):784-785. doi: 10.1016/j.ijantimicag.2017.04.002. PMID: 28412274.

    34. Allegra S, Fatiguso G, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Di Perri G, D'Avolio A. Role of vitamin D pathway gene polymorphisms on rifampicin plasma and intracellular pharmacokinetics. Pharmacogenomics. 2017 Jun;18(9):865-880. doi: 10.2217/pgs-2017-0176. PMID: 28594304.

    35. Allegra S, Cusato J, De Francia S, Pirro E, Massano D, Piga A, D'Avolio A. Deferasirox pharmacokinetic evaluation in β-thalassaemia paediatric patients. J Pharm Pharmacol. 2017 May;69(5):525-528. doi: 10.1111/jphp.12559. PMID: 27230486.

    36. Allegra S, De Francia S, Cusato J, Arduino A, Massano D, Longo F, Piga A, D'Avolio A. Deferasirox pharmacogenetic influence on pharmacokinetic, efficacy and toxicity in a cohort of pediatric patients. Pharmacogenomics. 2017 Apr;18(6):539-554. doi: 10.2217/pgs-2016-0176. PMID: 28346059.

    37. Allegra S, Fatiguso G, Baietto L, Corcione S, Favata F, Ariaudo A, Pagani N, Ranieri VM, De Rosa FG, Di Perri G, D'Avolio A. Pharmacogenomic influence on sepsis outcome in critically ill patients. Infez Med. 2017 Mar 1;25(1):45-49. PMID: 28353455.

    38. Allegra S, De Francia S, Longo F, Massano D, Cusato J, Arduino A, Pirro E, Piga A, D'Avolio A. Deferasirox pharmacokinetics evaluation in a woman with hereditary haemochromatosis and heterozygous β-thalassaemia. Biomed Pharmacother. 2016 Dec; 84:1510-1512. doi: 10.1016/j.biopha.2016.11.041. PMID: 27881236.

    39. Allegra S, De Francia S, Cusato J, Pirro E, Massano D, Piga A, D'Avolio A. Deferasirox pharmacokinetic and toxicity correlation in β-thalassaemia major treatment. J Pharm Pharmacol. 2016 Nov;68(11):1417-1421. doi: 10.1111/jphp.12638. PMID: 27672004.

    40. Allegra S, Cusato J, De Francia S, Massano D, Piga A, D'Avolio A. Deferasirox AUC efficacy cutoff and role of pharmacogenetics. Eur J Clin Pharmacol. 2016 Sep;72(9):1155-7. doi: 10.1007/s00228-016-2070-9. PMID: 27193993.

    41. D'Avolio A, Cusato J, De Nicolò A, Allegra S, Di Perri G. Pharmacogenetics of ribavirin-induced anemia in HCV patients. Pharmacogenomics. 2016 Jun;17(8):925-41. doi: 10.2217/pgs.16.22. Review. PMID: 27248282.

    42. Cusato J*, Allegra S*, De Francia S, Massano D, Piga A, D'Avolio A. Role of pharmacogenetics on deferasirox AUC and efficacy. Pharmacogenomics. 2016 Apr;17(6):561-72. doi: 10.2217/pgs-2015-0001. PMID: 27043265.

    43. Cusato J, Tomasello C, Simiele M, Calcagno A, Bonora S, Marinaro L, Leggieri A, Allegra S, Di Perri G, D'Avolio A. Efavirenz pharmacogenetics in a cohort of Italian patients. Int J Antimicrob Agents. 2016 Feb;47(2):117-23. doi: 10.1016/j.ijantimicag.2015.11.012. PMID: 26774523

    44. Fatiguso G*, Allegra S*, Calcagno A, Baietto L, Motta I, Favata F, Cusato J, Bonora S, Perri GD, D'Avolio A. Ethambutol plasma and intracellular pharmacokinetics: A pharmacogenetic study. Int J Pharm. 2016 Jan 30;497(1-2):287-92. doi: 10.1016/j.ijpharm.2015.11.044. PMID: 26642947.

    45. De Nicolò A, Abdi AM, Boglione L, Baiett L, Allegra S, Di Perri G, D'Avolio A. UPLC-MS/MS method with automated on-line SPE for the isomer-specific quantification of the first-generation anti-HCV protease inhibitors in peripheral blood mononuclear cells. J Pharm Biomed Anal. 2015 Nov 10;115:443-9. doi: 10.1016/j.jpba.2015.08.004. PMID: 26291788.

    46. De Nicolò A, Simiele M, Pensi D, Boglione L, Allegra S, Di Perri G, D'Avolio A. UPLC-MS/MS method for the simultaneous quantification of anti-HBV nucleos(t)ides analogs: Entecavir, lamivudine, telbivudine and tenofovir in
    plasma of HBV infected patients. J Pharm Biomed Anal. 2015 Oct 10;114:127-32. doi: 10.1016/j.jpba.2015.05.016. PMID: 26037161.

    47. Boglione L, Cusato J, Allegra S, Cariti G, Di Perri G, D'Avolio A. Role ofIL28B genotyping in patients with hepatitis C virus-associated mixed cryoglobulinemia and response to PEG-IFN and ribavirin treatment. Arch Virol. 2015 Aug;160(8):2009-17. doi: 10.1007/s00705-015-2482-3. PMID: 26060059.

    48. Cusato J*, Allegra S*, De Nicolò A, Boglione L, Fatiguso G, Abdi AM, Cariti G, Di Perri G, D'Avolio A. Intracellular accumulation of boceprevir according to plasma concentrations and pharmacogenetics. Int J Antimicrob Agents. 2015 Jun;45(6):657-61. doi: 10.1016/j.ijantimicag.2015.01.019 PMID: 25836019.

    49. Cusato J, Allegra S, Massano D, De Francia S, Piga A, D'Avolio A. Influence of single-nucleotide polymorphisms on deferasirox C trough levels and effectiveness. Pharmacogenomics J. 2015 Jun;15(3):263-71. doi: 10.1038/tpj.2014.65. PMID: 25348619.

    50. Cusato J*, Allegra S*, Boglione L, De Nicolò A, Cariti G, Di Perri G, D'Avolio A. VDR gene polymorphisms impact on anemia at 2 weeks of anti-HCV therapy: a possible mechanism for early RBV-induced anemia. Pharmacogenet Genomics. 2015 Apr;25(4):164-72. doi: 10.1097/FPC.0000000000000123. PMID: 25713999.

    51. Cusato J*, Allegra S*, De Nicolò A, Boglione L, Fatiguso G, Cariti G, Ciancio A, Smedile A, Strona S, Troshina G, Rizzetto M, Di Perri G, D'Avolio A. ABCB11 and ABCB1 gene polymorphisms impact on telaprevir pharmacokinetic at one month of therapy. Biomed Pharmacother. 2015 Feb;69:63-9. doi: 10.1016/j.biopha.2014.11.007. PMID: 25661339.

    52. Allegra S, Cusato J, De Nicolò A, Boglione L, Gatto A, Cariti G, Di Perri G, D'Avolio A. Role of pharmacogenetic in ribavirin outcome prediction and pharmacokinetics in an Italian cohort of HCV-1 and 4 patients. Biomed Pharmacother. 2015 Feb;69:47-55. doi: 10.1016/j.biopha.2014.10.030. PMID: 25661337.

    53. Cusato J*, Allegra S*, Boglione L, De Nicolò A, Baietto L, Cariti G, Di Perri G, D'Avolio A. Vitamin D pathway gene variants and HCV-2/3 therapy outcomes. Antivir Ther. 2015;20(3):335-41. doi: 10.3851/IMP2853. PMID: 25279449.

    54. Cusato J, Allegra S, De Nicolò A, Boglione L, Fatiguso G, Mohamed Abdi A, Cariti G, Di Perri G, D'Avolio A. Intracellular and Plasma Trough Concentration and Pharmacogenetics of Telaprevir. J Pharm Pharm Sci. 2015;18(2):171-6. PMID: 26158282.

    55. D'Avolio A, Carcieri C, Cusato J, Simiele M, Calcagno A, Allegra S, Sciandra M, Trentini L, Di Perri G, Bonora S. Intracellular accumulation of atazanavir/ritonavir according to plasma concentrations and OATP1B1, ABCB1 and PXR genetic polymorphisms. J Antimicrob Chemother. 2014 Nov;69(11):3061-6. doi: 10.1093/jac/dku234. PubMed PMID: 24997317.

    56. Boglione L, Cusato J, De Nicolò A, Cariti G, Allegra S, Ghisetti V, Di Perri G, D'Avolio A. Identification of naïve HVC-4 patients who may be treated with pegylated-interferon and ribavirin according to IL28B polymorphisms. Antiviral Res. 2014 Jun;106:105-10. doi: 10.1016/j.antiviral.2014.03.016. PMID: 24726902.

    57. Boglione L, Cusato J, Allegra S, Esposito I, Patti F, Cariti G, Di Perri G, D'Avolio A. Role of IL28-B polymorphisms in the treatment of chronic hepatitis B HBeAg-negative patients with peginterferon. Antiviral Res. 2014 Feb;102:35-43. doi: 10.1016/j.antiviral.2013.11.014. PMID: 24316030.

    Insegnamenti

    Gruppi di ricerca

    Progetti di ricerca

    Attività in agenda

    Consulta la mia agenda

    Ultimo aggiornamento: 12/07/2023 13:48
    Location: https://www.dscb.unito.it/robots.html
    Non cliccare qui!